Effect of Inflammatory Microenvironment on the Regenerative Capacity of Adipose-Derived Mesenchymal Stem Cells

Cells. 2023 Jul 29;12(15):1966. doi: 10.3390/cells12151966.

Abstract

Adipose-derived mesenchymal stem cells are increasingly being used in regenerative medicine as cell therapy targets, including in the treatment of burns and ulcers. The regenerative potential of AD-MSCs and some of their immunological properties are known from in vitro studies; however, in clinical applications, cells are used in non-ideal conditions and can behave differently in inflammatory environments, affecting the efficacy and outcome of therapy. Our aim was to investigate and map the pathways that the inflammatory microenvironment can induce in these cells. High-throughput gene expression assays were performed on AD-MSCs activated with LPS and TNFα. Analysis of RNA-Seq data showed that control, LPS-treated and TNFα-treated samples exhibited distinct gene expression patterns. LPS treatment increased the expression of 926 genes and decreased the expression of 770 genes involved in cell division, DNA repair, the cell cycle, and several metabolic processes. TNFα treatment increased the expression of 174 genes and decreased the expression of 383 genes, which are related to cell division, the immune response, cell proliferation, and differentiation. We also map the biological pathways by further investigating the most altered genes using the Gene Ontology and KEGG databases. Secreted cytokines, which are important in the immunological response, were also examined at the protein level, and a functional assay was performed to assess wound healing. Activated AD-MSC increased the secretion of IL-6, IL-8 and CXCL-10, and also the closure of wounds. AD-MSCs presented accelerated wound healing under inflammation conditions, suggesting that we could use this cell in clinical application.

Keywords: adipose-derived mesenchymal stem cells; inflammation; lipopolysaccharide; regenerative medicine; tumor necrosis factor α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation
  • Cytokines / metabolism
  • Lipopolysaccharides / pharmacology
  • Mesenchymal Stem Cells* / metabolism
  • Tumor Necrosis Factor-alpha* / metabolism

Substances

  • Tumor Necrosis Factor-alpha
  • Lipopolysaccharides
  • Cytokines

Grants and funding

This work was supported by the National Research, Development and Innovation Office (NKFI PD 132570 to Z.V.) and the GINOP PLUSZ-2.1.1-21 project (co-financed by the European Union and the European Regional Development Fund) Z.V. was supported by the Bolyai János Postdoctoral Fellowship (BO/00190/20/5) and the NKP-22-5 Bolyai + Fellowship (NKP-NKP-22-5-SZTE-319) financed by the New National Excellence Program of the Hungarian Ministry of Innovation and Technology from the source of the National Research Development and Innovation Fund. Project no. TKP2021-EGA-28 and TKP2021-EGA-32 have been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-EGA funding scheme. LK was supported by the New National Excellence Program of the Hungarian Ministry of Innovation and Technology from the source of the National Research Development and Innovation Fund. K.L-HCEMM: H2020-EU.4.a. The research was supported by the Biobank Competence Center of the Life Sciences Cluster of the Centre of Excellence for Interdisciplinary Research, Development, and Innovation of the University of Szeged. Vanda Miklós is a member of the Biobank research group.